Trials / Active Not Recruiting
Active Not RecruitingNCT04447833
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Uppsala University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 | Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs). |
Timeline
- Start date
- 2020-06-17
- Primary completion
- 2021-01-30
- Completion
- 2026-03-30
- First posted
- 2020-06-25
- Last updated
- 2025-04-25
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT04447833. Inclusion in this directory is not an endorsement.